Cellestial Health has been named as one of the 10 global finalists in the Second Annual Life Sciences Innovation Summit organised by J.P. Morgan Asset Management’s Life Sciences Private Capital and King Abdullah International Medical Research Center (كيمارك KAIMRC), alongside EpiBone, Inc., FimmCyte Therapeutics, Genethon NewCo, NanoPalm | نانو بالم, Neurenati Therapeutics, Rinri Therapeutics, Script Biosciences, Synthis Therapeutics, Inc., and Ten30 Biosciences Inc.
The Summit will take place on October 1-2, 2025 in Riyadh, Saudi Arabia.
Read the full press release on the J.P. Morgan Asset Management website:
https://am.jpmorgan.com/us/en/asset-management/adv/about-us/media/press-releases/jp-morgan-life-sciences-private-capital-and-king-abdullah-international-medical-research-center-announce-finalists-of-second-annual-life-sciences-innovation-summit-in-riyadh-saudi-arabia/
Cellestial Health is global from early stages, because #Parkinsons is.
See you in the sunny #Riyadh!